Share This Article:

Botulinum Toxin-A for the Treatment of Voiding Dysfunction: Our Initial Experience

Abstract Full-Text HTML Download Download as PDF (Size:189KB) PP. 67-71
DOI: 10.4236/oju.2012.22011    2,884 Downloads   5,247 Views  

ABSTRACT

Objective: Evaluation of Botulinum Toxin-A (BTX-A) as an alternative treatment option in patients whom previous treatments were failed. Methods: Between March 2005 and September 2006, a total 19 patients; 16 patients with overactive bladder (5 neurologic, 11 idiopathic), 2 with nocturnal enuresis, 1 with interstitial cystitis, intravesical BTX-A injection was applied. Except one patient, 18 patients with a median age 46 (20 - 80) were registered to the study. Patients were examined at postoperative 3 weeks and 6 months with ICIQ-SF (International Consultation on Incontinence Questionnaire-Short Form) and satisfaction forms used in our clinic. Results: The median follow-up time was 16 months (6 - 18). When evaluated according to diagnosis, symptoms were improved 100% in neurologic overactive bladder (5/5), 80% in idiopathic overactivity (8/10), 50% in nocturnal enuresis (1/2). In one patient with interstitial cystitis there was no improvement. Median efficiency time of BTX-A treatment was 6 months (1 - 17). At 3 weeks and 6 months after the treatment, ICIQ-SF score was decreased to 3.6 and 7.5 respectively from preoperative level of 18.7. Quality of life scores at preoperative, 3 week and 6 months were 9.7, 2.7 and 4.3 respectively. Except 3 patients with overactive neurologic bladder because of spinal cord injury, symptoms of patients with pollacuria and nocturia decreased at 3. week. Even if these rates increased at 6 months they still were significantly less than preoperative status. The spinal cord injured 3 patients had clean intermittent catheterization per 1 hour and had urinary incontinence between the catheterizations preoperatively, however at 3 weeks and 6 months the intervals of catheterisations was 4 hours and 3 hours respectively and also the urinary incontinance between the catheterisations improved. At patient satisfactions, 78% of patients declared that they were pleased and underwent the procedure again and will recommend it to their relatives with similar problems. One patient had a complication as tansient weakness on her legs. Conclusion: BTX-A injections provide an alternative treatment before surgery at overactive bladder especially for those who doesn’t response to medical treatment or cannot use antimuscarinics because of their side effects. Further studies with a greater number of patients are needed for determining the effectiveness of BTX-A on patients with voiding dysfunctions.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. Citgez, B. Onal, F. Gevher, C. Dogan, O. Kurt, O. Demirkesen and B. Cetinel, "Botulinum Toxin-A for the Treatment of Voiding Dysfunction: Our Initial Experience," Open Journal of Urology, Vol. 2 No. 2, 2012, pp. 67-71. doi: 10.4236/oju.2012.22011.

References

[1] E. Van Ermengem, “A New Anaerobic Bacillus and Its Relation to Botulism,” Clinical Infectious Diseases, Vol. 1, No. 4, 1979, pp. 701-709. doi:10.1093/clinids/1.4.701
[2] C. L. Comella, M. Brin and J. Jankovic, “Biochemistry of Botulinum Toksin Type B,” Neurology, Vol. 55, No. 12, 2000, pp. 22-28.
[3] A. S. V. Burgen, F. Dickens and L. J. Zatman, “The Action of Botulinum Toxin on the Neuromuscular Junction,” Journal of Physiology, Vol. 109, No. 1-2, 1949, pp. 10-24.
[4] A. B. Scott, “Botulinum Toxin Injection into Extraocular Muscles as an Alternative to Strabismus Surgery,” Journal of Pediatic Ophtalmology and Strabismus, Vol. 17, No. 10, 1980, pp. 1044-1049.
[5] D. D. Dykstra, A. A. Sidi, A. B. Scott, et al., “Effects of Botulinum A Toxin on Detrusorsphincter Dyssynergia in Spinal Cord Injury Patients,” The Journal of Urology, Vol. 139, No. 2, 1988, pp. 919-922.
[6] H. C. Kuo, “Botulinum A Toxin Urethral Injection for the Treatment of Lower Urinary Tract Dysfunction,” The Journal of Urology, Vol. 170, No. 5, 2003, pp. 1908-1912. doi:10.1097/01.ju.0000091281.50081.f0
[7] B. Schurch, M. Stohrer, G. Kramer, et al., “Botulinum-A Toxin for Treating Detrusor Hyperreflexia in Spinal Cord Injured Patients: A New Alternative to Anticholinergic Drugs Preliminary Results,” The Journal of Urology, Vol. 164, No. 3, 2000, pp. 692-697. doi:10.1016/S0022-5347(05)67283-7
[8] M. Chancellor, M. O’Leary, J. Erickson, et al., “Successful Use of Bladder Botulinum Toxin Injection to Treat Refractory Overactive Bladder,” The Journal of Urology, Vol. 169, Suppl. 4, 2003, p. 351.
[9] D. Zermann, M. Ishigooka, J. Schubert, et al., “Perisphincteric Injection of Botulinum Toxin Type A: A Treatment Option for Patients with Chronic Prostatic Pain?” European Urology, Vol. 38, No. 4, 2000, pp. 393-399. doi:10.1159/000020314
[10] S. K. Jarvis, J. A. Abbott, M. B. Lenart, et al., “Pilot Study of Botulinum Toxin Type A in the Treatment of Chronic Pelvic Pain Associated with Spasm of the Levator Ani Muscles,” Australian and New Zealand Journal of Obstetics and Gynaecology, Vol. 44, No. 1, 2004, pp. 46-50. doi:10.1111/j.1479-828X.2004.00163.x
[11] M. Khera, T. B. Boone and C. P. Smith., “Botulinum Toxin Type A: A Novel Approach to the Treatment of Recurrent Urethral Strictures,” The Journal of Urology, Vol. 172, No. 2, 2004, pp. 574-575. doi:10.1097/01.ju.0000130652.27541.22
[12] P. Abrams, L. Cardozo, M. Fall, et al., “The Standardization of Terminology of Lower Urinary Tract Function: Report from the Standardisation Sub-Committee of the International Continence Society,” Neurourology and Urodynamics, Vol. 21, No. 2, 2002, pp. 167-178. doi:10.1002/nau.10052
[13] T. M. Kessler, H. Danuser, M. Schumacher, et al., “Botulinum A Toxin Injections into the Detrusor: An Effective Treatment in Idiopathic and Neurogenic Detrusor Overactivity?” Neurourology and Urodynamics, Vol. 24, No. 3, 2005, pp. 231-236. doi:10.1002/nau.20105
[14] R. Popat, A. Apostolidis, V. Kalsi, et al., “Comparison between the Response of Patients with Idiopathic Detrusor Overactivity and Neurogenic Detrusor Overactivity to the First Intradetrusor Injection of Botulinum-A Toxin,” The Journal of Urology, Vol. 174, No. 2, 2005; pp. 984-989. doi:10.1097/01.ju.0000169480.43557.31
[15] M. Harper, R. B. Popat, R. Dasgupta, et al., “Minimally Invasive Technique for Outpatient Local Anaesthetic Administration of Intradetrusor Botulinum Toxin in Intractable Detrusor Overactivity,” BJU International, Vol. 92, No. 3, 2003; pp. 325-326. doi:10.1046/j.1464-410X.2003.04312.x
[16] D. E. Rapp, A. Lucioni, E. E. Katz, et al., “Use of Botulinum-A Toxin for the Treatment of Refractory Overactive Bladder Symptoms: An Initial Experience,” Urology, Vol. 63, No. 3, 2004, pp. 1071-1075. doi:10.1016/j.urology.2004.01.041
[17] C. P. Smith and M. B. Chancellor, “The Emerging Role of Botulinum Toxin in the Management of Voiding Dysfunction,” The Journal of Urology, Vol. 171, No. 6, 2004, pp. 2128-2137. doi:10.1097/01.ju.0000127725.48479.89
[18] C. P. Smith, S. Nishuguchi, M. O’Leary, et al., “Single Institution Experience in 110 Patients with Botilinum A Toxin Injection into Bladder or Urethra,” Urology, Vol. 65, No. 1, 2005, pp. 37-41. doi:10.1016/j.urology.2004.08.016
[19] H. Schulte-Baukloh, T. Michael, B. Sturzebecher, et al., “Botulinum-A Toxin Detrusor Injection as a Novel Approach in the Treatment of Bladder Spasticity in Children with Neurogenic Bladder,” European Urology, Vol. 44, No. 1, 2003, pp. 139-143. doi:10.1016/S0302-2838(03)00136-2
[20] A. Reitz, M. Stohrer, G. Kramer, et al., “European Experience of 200 Cases Treated with Botulinum-A Toxin Injections into the Detrusor Muscle for Urinary Incontinence Due to Neurogenic Detrusor Overactivity,” European Urology, Vol. 45, No. 4, 2004, pp. 510-515. doi:10.1016/j.eururo.2003.12.004
[21] T. L. Frenkl and R. R. Rackley, “Injectable Neuromodulatory Agents: Botulinum Toxin Therapy,” Urologic Clinics of North America, Vol. 32, No. 1, 2005, pp. 89-99. doi:10.1016/j.ucl.2004.09.005
[22] C. P. Smith, S. Nishuguchi, M. O’Leary, et al., “Single Institution Experience in 110 Patients with Botilinum A Toxin Injection into Bladder or Urethra,” Urology, Vol. 65, No. 1, 2005, pp. 37-41. doi:10.1016/j.urology.2004.08.016
[23] I. F. Ghalayini and M. A. Al-Ghazo, “Intradetrusor Injection of Botulinum-A Toxin in Patients with Idiopathic and Neurogenic Detrusor Overactivity: Urodynamic Outcome and Patient Satisfaction,” Neurourology and Urodynamics, Vol. 26, No. 4, 2007, pp. 531-536. doi:10.1002/nau.20403

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.